Article
Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (p.G12C) mutation.
Cancer science - 1 Oct 2024
Ugai Satoko, Yao Qian, Takashima Yasutoshi, Zhong Yuxue, Matsuda Kosuke, Kawamura Hidetaka, Imamura Yu, Okadome Kazuo, Mima Kosuke, Arima Kota, Kosumi Keisuke, Song Mingyang, Meyerhardt Jeffrey A, Giannakis Marios, Nowak Jonathan A, Ugai Tomotaka, Ogino Shuji
Abstract excerpt
Evidence indicates that combinations of anti-EGFR antibodies and KRAS p.G12C (c.34G>T) inhibitors can be an effective treatment strategy for advanced colorectal cancer. We hypothesized that KRAS c.34G>T (p.G12C)-mutated colorectal carcinoma might be a distinct tumor subtype. We utilized a prospec...
Topics
- Humans
- Colorectal Neoplasms
- Proto-Oncogene Proteins p21(ras)
- Female
- Male
- Aged
- Mutation
- Middle Aged
- Prognosis
- DNA Methylation
- CpG Islands
- Prospective Studies
- Proto-Oncogene Proteins B-raf